- Planning for fertility preservation before cancer treatment. Oktay, Kutluk; Meirow, Dror // Journal of Family Practice;Apr2007 Supplement, Vol. 56, p17
The article provides information how to preserve fertility in patients receiving cancer treatment, including chemotherapy, radiation therapy, hormone therapy or the combination of these therapies in the U.S. The effects of cancer treatment on fertility or reproductive capacity of both men and...
- ASCO updates guideline on pharmacologic interventions for breast cancer risk reduction. // Hem/Onc Today;6/25/2009, Vol. 10 Issue 12, p43
The article reports on the updates made by the American Society of Clinical Oncology (ASCO) to its clinical practice guideline on pharmacologic interventions for breast cancer risk reduction.
- New targets, new drugs highlight oncology meeting. McCann, Jean // Drug Topics;6/4/2001, Vol. 145 Issue 11, p27
Highlights the 2001 meeting of the American Society of Clinical Oncology. Conclusion of the phase I clinical trial of EntreMed's angiostatin inhibitor endostatin; Treatment for cancers.
- ASCO releases Disparities in Cancer Care recommendations. Harris, Jason // Hem/Onc Today;5/25/2009, Vol. 10 Issue 10, p63
The article deals with the policy statement released by the American Society of Clinical Oncology (ASCO) in April 2009 on disparities in cancer care, giving particular focus on new initiatives to improve cancer care for the elderly and minorities.
- Tracking a cancer cure. Marcus, Mary Brophy // U.S. News & World Report;06/01/98, Vol. 124 Issue 21, p52
Summarizes new cancer studies presented at the May, 1998 meeting of the American Society of Clinical Oncology. Drugs called Camptosar, Taxol, and Herceptin; Use of selective estrogen receptor modulators, or SERMs; Prostate specific antigen (PSA) blood tests; Smoking and the development of...
- New Biologic Agent May Benefit Men with CRPC. Schieszer, John // Renal & Urology News;Aug2010, Vol. 9 Issue 8, p4
The article reports on the study about a novel biologic agent that may significantly slow the rate of disease progression and improve progression-free survival in patients with metastatic castrationresistant prostate cancer (CRPC) that was presented at the American Society of Clinical Oncology...
- ASCO's "top five" costly overused ealthcare reform interventions. // PharmacoEconomics & Outcomes News;4/28/2012, Issue 652, p2
The article reports on the top five costly overused cancer interventions identified by the American Society of Clinical Oncology (ASCO), including computed tomography (CT) or radionuclide bone scans (RBS), surveillance biomarker testing or imaging and white cell stimulating factors.
- Beyond chemotherapy: Cancer researchers try genetic routes. // Medical Marketing & Media;Jul97, Vol. 32 Issue 7, p21
Details new methods developed to kill cancer cells, presented at the American Society of Clinical Oncology's (ASCO) annual meeting in Denver. Gene transfer technologies for the treatment of metastatic melanoma; Antisense therapy to block the production of damaging proteins; Use of a virus to...
- Second line therapies move to the forefront in colorectal cancer. Miller, Mike; Miller, M // JNCI: Journal of the National Cancer Institute;06/16/99, Vol. 91 Issue 12, p998
Focuses on the drugs CPT-11 and oxaliplatin for the treatment of metastatic colorectal cancer introduced during the annual meeting of the American Society of Clinical Oncology in Atlanta. Effectiveness of the drug; Actual benefits of the drugs to patients; Results of the trial on the efficacy of...